COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae312 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Camille Mehlman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Pa…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.
Methods
COMPOSIT was a French, retrospective, multicenter, cohort study of the effectiveness and tolerability of osimertinib in combination with other targeted therapies in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) who harbored other oncogenic drivers as primary or acquired resistance mechanisms. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate (ORR) were the primary endpoints.
Results
The study included 61 patients (63.9% women; median age, 61 years). Chemotherapy was administered to 26 patients (42.6%) before the combinations. The most frequently targeted resistance mechanisms were MET amplification (n = 40) and BRAF alterations (n = 11). Sixteen combinations of osimertinib with other targeted therapies were reported. Overall (except for 10 patients in clinical trials), median rwPFS and OS were 3.9 (95% CI, 2.9-5.2) and 9.8 months (95% CI, 6.8-14.8). Best ORR (n = 54) was 50% (95% CI, 33.0-72.8). In patients with MET amplification (n = 29), median rwPFS and OS were 4.9 (95% CI, 2.9-7.2) and 8.6 months (95% CI, 5.3-21.6). Grade ≥3 adverse events occurred in 15 patients (24.6%). No deaths were related to treatment.
Conclusions
Combinations of osimertinib with other targeted therapies appeared to be feasible and safe and may offer clinical benefit to overcome resistance to osimertinib in EGFRm NSCLC, especially in patients with MET amplification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France.
- Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon, France.
- Univ Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Leon Bérard, Cancer Research Center of Lyon, Lyon, France.
- Department of Pneumology, Centre Hospitalier Inter-Communal de Creteil (CHIC), Creteil, France.
- Department of Thoracic Oncology, Centre Hospitalier Universitaire Larrey, Toulouse, France.
- Unité d'Oncologie Thoracique Service de Pneumologie Hopital Cochin, AP-HP Equipe "cancer, immune control and escape" Inserm U1138 Centre de Recherches des Cordeliers Université Paris Cité, France.
ORCID-Profile: Vincent Fallet
Zitieren
APA
Mehlman, C., Swalduz, A., Monnet, I., Morin, C., Wislez, M., Guisier, F., Curcio, H., Du Rusquec, P., Cortot, A. B., Gounant, V., Abbar, B., Duchemann, B., Giroux-Leprieur, E., Pierret, T., Quilot, F. M., Cadranel, J., & Fallet, V. (2025). COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae312
Vancouver
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, et al. COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyae312
BibTeX
@article{Mehlman2025,
author = {Mehlman, Camille and Swalduz, Aurelie and Monnet, Isabelle and Morin, Clara and Wislez, Marie and Guisier, Florian and Curcio, Hubert and Du Rusquec, Pauline and Cortot, Alexis B and Gounant, Valerie and Abbar, Baptiste and Duchemann, Boris and Giroux-Leprieur, Etienne and Pierret, Thomas and Quilot, Fleur-Marie and Cadranel, Jacques and Fallet, Vincent},
title = {COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae312}
}
EUVIMED